1,2,3-thiadiazoles (including Hydrogenated) Patents (Class 548/127)
-
Patent number: 6664277Abstract: The present invention is directed to compounds useful in the treatment of diseases associated with prenylation of proteins and pharmaceutically acceptable salts thereof, to pharmaceutical compositions comprising same, and to methods for inhibiting protein prenylation in an organism using the same.Type: GrantFiled: January 3, 2003Date of Patent: December 16, 2003Assignee: PPD Discovery, Inc.Inventors: Bradley B. Brown, Kenneth S. Rehder, Jon-Paul Strachan, Jeron H. Eaves, Christopher T. Lowden
-
Patent number: 6646149Abstract: Novel “bispolyamine” inhibitor compounds of polyamine transport are disclosed. These compounds are useful pharmaceutical agents for treating diseases where it is desired to inhibit polyamine transport or other polyamine binding proteins, for example cancer and post-angioplasty injury. These compounds display desirable activities both for diagnostic and research assays and therapy.Type: GrantFiled: May 31, 2000Date of Patent: November 11, 2003Inventors: Nicolaas M. J. Vermeulin, Christine L. O'Day, Heather K. Webb, Mark R. Burns, Donald E. Bergstrom
-
Patent number: 6645951Abstract: The present invention provides novel benzopyran compounds, pharmaceutically acceptable salts thereof and stereoisomers thereof where the benzopyran compounds of the invention are compounds according to Formula I: The present invention further provides pharmaceutical compositions which possess anti-estrogenic activity and comprise at least one benzopyran compound of the invention and a method of treating breast cancer by administration of an effective amount of a benzopyran compound provided by the present invention.Type: GrantFiled: July 16, 2001Date of Patent: November 11, 2003Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Jae Chon Jo, Hyun Suk Lim, Jong Min Kim, Ju Su Kim, Kazumi Morikawa, Yoshitake Kanbe, Myung Hwa Kim, Masahiro Nishimoto
-
Publication number: 20030187259Abstract: The present invention relates to novel heterocyclic fluoroalkenyl thioethers of the formula (I) 1Type: ApplicationFiled: May 12, 2003Publication date: October 2, 2003Inventors: Udo Kraatz, Bernd Gallenkamp, Albrecht Marhold, Peter Wolfrim, Wolfram Andersch, Christoph Erdelen, Andreas Turberg, Olaf Hansen, Achim Harder
-
Patent number: 6610710Abstract: Phenylalanine derivatives of the following formula and analogues thereof have an antagonistic activity to &agr;4&bgr;7 integrin and a selectivity toward &agr;4&bgr;1 integrin. They are used as therapeutic agents for various diseases to which &agr;4&bgr;7 integrin relates.Type: GrantFiled: June 28, 2002Date of Patent: August 26, 2003Assignee: Ajinomoto Co., Inc.Inventors: Yasuhiro Tanaka, Toshihiko Yoshimura, Chieko Ejima, Mitsuhiko Kojima, Eiji Nakanishi, Hiroyuki Izawa, Yuko Satake, Nobuyasu Suzuki, Manabu Suzuki, Masahiro Murata
-
Patent number: 6605630Abstract: The invention concerns a compound of the formula (I): wherein, for example: T is of the formula (IA), (IB), or (IC); R1 is of the formula —NHC(═O)Rb wherein Rb is (1-4C)alkyl; R2 and R3 are hydrogen or fluoro; >A—B— is >C═CH— (but not when T is (IA)) or >CH—CH2—; wherein when T is of the formula (IA) or (IB); R6 is, for example, (1-4C)alkyl; R5 is hydrogen, R10CO—, R10SO2— or R10CS— wherein R10 is, for example, optionally substituted phenyl, or (1-10C)alkyl, or when T is of the formula (IA), (IB); or (IC): R5 and R6 are linked to give a 5- or 6-membered ring which is fused to the ring shown in (IA), (IB), or (IC) so as to give an optionally substituted bicyclic ring; and pharmaceutically acceptable salts thereof, processes for their preparation, pharmaceutical compositions containing them, and their use as antibacterial agents.Type: GrantFiled: February 18, 2000Date of Patent: August 12, 2003Assignee: Syngenta LimitedInventor: Michael Barry Gravestock
-
Publication number: 20030134853Abstract: A series of compounds of Formula I are disclosed which are useful in treating viral hepatitus C.Type: ApplicationFiled: September 26, 2002Publication date: July 17, 2003Inventors: Eldon Scott Priestley, Carl P. Decicco, Thomas W. Hudyma, Xiaofan Zheng
-
Patent number: 6593357Abstract: Described herein are compounds that are useful as protein kinase inhibitors having the formula: where R1-4, Q, and T are described in the specification. The compounds are useful for treating disease states in mammals that are alleviated by a protein kinase inhibitor, particularly diseases such as cancer, inflammatory disorders, restenosis, and cardiovascular disease.Type: GrantFiled: August 22, 2002Date of Patent: July 15, 2003Assignee: Vertex Pharmaceuticals IncorporatedInventors: Jeremy Green, Jingrong Cao, Michael Hale, Christopher Baker, Francois Maltais, James Janetka, Michael Mullican, Guy Bemis, Xiaoling Xie, Judith Straub, Qing Tang
-
Patent number: 6589914Abstract: The dihalopropene compounds of the general formula (I) have excellent insecticidal/acaricidal activity, so that they are satisfactorily effective for the control of noxious insects, mites and ticks.Type: GrantFiled: March 4, 2002Date of Patent: July 8, 2003Assignee: Sumitomo Chemical Company, LimitedInventors: Noriyasu Sakamoto, Sanshiro Matsuo, Masaya Suzuki, Taro Hirose, Kazunori Tsushima, Kimitoshi Umeda
-
Patent number: 6569876Abstract: The present invention is directed to novel inhibitors and methods for inhibiting serine elastases. These compounds and methods achieve a novel approach to enzyme inhibition; namely, balanced inhibition of a plurality of serine elastases. Balanced inhibition of a plurality of elastases offers a novel approach to therapeutic treatment of diseases that involve abnormal activities of a plurality of elastases resulting in pathological changes such as occur in inflammatory and vascular conditions. These pathological changes are not limited to the breakdown of elastin but may include the processing of other proteins by serine elastases which in turn results in adverse effects. The opportunity of targeting a plurality of enzymes using single inhibitor offers therapeutic advantages over administering multiple therapeutic against where each agent has a single specificity for an individual target enzyme.Type: GrantFiled: June 19, 2000Date of Patent: May 27, 2003Inventor: John C. Cheronis
-
Publication number: 20030096848Abstract: Pharmaceutical compositions and compounds are provided. The compounds of the invention have anti-proliferative activity, and may promote apoptosis in cells lacking normal regulation of cell cycle and death. In one embodiment of the invention, formulations of the compounds in combination with a physiologically acceptable carrier are provided. The pharmaceutical formulations are useful in the treatment of hyperproliferative disorders, which disorders include tumor growth, lymphoproliferative diseases, angiogenesis.Type: ApplicationFiled: May 10, 2002Publication date: May 22, 2003Inventors: Zaihui Zhang, Gregory B. Chopiuk, Timothy S. Daynard, Shisen Wang
-
Publication number: 20030069237Abstract: The present application describes nitrogen containing heterobicyclics and derivatives thereof, or pharmaceutically acceptable salt forms thereof, which are useful as inhibitors of factor Xa.Type: ApplicationFiled: April 26, 2002Publication date: April 10, 2003Inventors: John M. Fevig, Joseph Cacciola, Charles G. Clark, Qi Han, Patrick Yuk Sun Lam, Donald J.P. Pinto, James R. Pruitt, Mimi L. Quan, Karen A. Rossi
-
Patent number: 6541423Abstract: The invention relates to pyrazolyl derivatives of benzo-condensated, unsaturated 5-membered nitrogen heterocycles of the general formula (I), wherein X represents N or a group C—R3; Y is O, S, SO, SO2 or NR4 or X—Y is S═N, and wherein X means sulfur, and the variables R1, R2 and Pz have the meanings indicated in claim 1. The invention, further relates to a method of producing said compounds, to agents that contain them and to their use as herbicidal agents.Type: GrantFiled: November 1, 2001Date of Patent: April 1, 2003Assignee: BASF AktiengesellschaftInventors: Guido Mayer, Ernst Baumann, Wolfgang von Deyn, Steffen Kudis, Klaus Langemann, Ulf Misslitz, Ulf Neidlein, Matthias Witschel, Michael Rack, Thorsten Volk, Martina Otten, Karl-Otto Westphalen, Helmut Walter
-
Patent number: 6528509Abstract: Described herein are compounds that are useful as protein kinase inhibitors having the formula: where R1-4, Q, and T are described in the specification. The compounds are useful for treating disease states in mammals that are alleviated by a protein kinase inhibitor, particularly diseases such as cancer, inflammatory disorders, restenosis, and cardiovascular disease.Type: GrantFiled: October 5, 2001Date of Patent: March 4, 2003Assignee: Vertex Pharmacuticals, IncorporatedInventors: Michael Hale, Xiaoling Xie, Jeremy Green, Jingrong Cao, Christopher Baker, Francois Maltais, James Janetka, Guy Bemis, Michael Mullican, Judith Straub, Qing Tang, Robert Mashal
-
Patent number: 6525086Abstract: The present invention relates to compounds of formula (I) wherein R1, R2, R3, R4, R5, R6, R7, R8, A, X, T, Q, Z, U, Y, Ar, p and n are as defined in the specification. These compounds are useful in the treatment and/or prevention of conditions mediated by nuclear receptors, in particular the Peroxisome Proliferator-Activated Receptors (PPAR).Type: GrantFiled: March 14, 2001Date of Patent: February 25, 2003Assignee: Novo Nordisk A/SInventors: Lone Jeppesen, Paul Stanley Bury, Per Sauerberg
-
Patent number: 6515124Abstract: Aromatic dehydroamino acids are disclosed that are active as LFA-1 arnagonists This activity enables these compounds to prevent inflammation which is a consequence of T cell activation and accordingly reduce or eliminate inflammatory skin disease psoriasis.Type: GrantFiled: January 5, 2001Date of Patent: February 4, 2003Assignee: Hoffman-La Roche Inc.Inventors: Nader Fotouhi, Paul Gillespie, Robert William Guthrie, Sherrie Lynn Pietranico-Cole, Weiya Yun
-
Patent number: 6506757Abstract: A peroxisome proliferator activated receptor regulator containing a carboxylic acid derivative of formula (I) (wherein all symbols are as defined in the specification), a non-toxic acid thereof or a hydrate thereof as active ingredient. Because of having an effect of regulating PPAR, a compound of formula (I) is useful as a hypoglycemic agent, a hypolipidemic agent, a preventive and/or a remedy for diseases associating metabolic disorders (diabetes, obesity, syndrome X, hypercholesterolemia, hyperlipoproteinemia, etc.), hyperlipemia, atherosclerosis, hypertension, circulatory diseases, overeating, coronary heart diseases, etc., an HDL cholesterol-elevating agent, an LDL cholesterol and/or VLDL cholesterol-lowering agent and a drug for relief from risk factors of diseases or syndrome X.Type: GrantFiled: September 11, 2000Date of Patent: January 14, 2003Assignee: ONO Pharmaceutical Co., Ltd.Inventors: Hisao Tajima, Yoshisuke Nakayama, Daikichi Fukushima
-
Patent number: 6469036Abstract: The present invention relates to a series of peptidyl heterocyclic ketones which are inflammatory cell serine protease inhibitors and their compositions and methods for the prevention and treatment of a variety of immunomediated inflammatory disorders. More particularly, these compounds are potent and selective inhibitors of tryptase and are therefore effective for the prevention and treatment of inflammatory diseases associated with the respiratory tract, such as asthma and allergic rhinitis.Type: GrantFiled: January 13, 2000Date of Patent: October 22, 2002Assignee: Ortho-McNeil Pharmaceutical, Inc.Inventors: Michael J. Costanzo, Bruce E. Maryanoff, Stephen C. Yabut
-
Patent number: 6462060Abstract: Compounds with heterocyclic-hydroxyimino-fluorene nuclei that modulate and/or inhibit the activity of certain protein kinases are described. These compounds and pharmaceutical compositions containing them are capable of mediating tyrosine kinase signal transduction in order to modulate and/or inhibit unwanted cell proliferation. The invention is also directed to the therapeutic or prophylactic use of pharmaceutical compositions containing such compounds, and to methods of treating cancer as well as other disease states associated with unwanted angiogenesis and/or cellular proliferation, such as diabetic retinopathy, glaucoma, rheumatoid arthritis, and psoriasis, by administering effective amounts of such compounds.Type: GrantFiled: August 16, 2001Date of Patent: October 8, 2002Assignee: Agouron Pharmaceuticals, Inc.Inventors: Wesley Kwon Mung Chong, Rohit Kumar Duvadie
-
Patent number: 6448281Abstract: A compound of the formula I: wherein: X is CH or N; Y is O or S; Z is OH, NH2, NMeR3, NHR3; OR3 or 5- or 6-membered heterocycle, having 1 to 4 heteroatoms selected from O, N and S, said heterocycle being optionally substituted with from 1 to 4 substituents; A is N, COR7 or CR5, wherein R5 is H, halogen, or (C1-6) alkyl and R7 is H or (C1-6 alkyl), with the proviso that X and A are not both N; R6 is H, halogen, (C1-6 alkyl) or OR7, wherein R7 is H or (C1-6 alkyl); R1 is selected from the group consisting of 5- or 6-membered heterocycle having 1 to 4 heteroatoms selected from O, N, and S, phenyl, phenyl(C1-3)alkyl, (C2-6)alkenyl, phenyl(C2-6)alkenyl, (C3-6)cycloalkyl, (C1-6)alkyl, CF3, 9- or 10-membered heterobicycle having 1 to 4 heteroatoms selected from O, N and S, wherein said heterocycle, phenyl, phenyl(C2-6)alkenyl and phenyl(C1-3)alkyl), alkenyl, cycloalkyl, (C1-6)alkyl, and heterobicycle are all optionally substituted with from 1 to 4 substituents; R2 is selected from (C1-6)alkyl, (CType: GrantFiled: July 3, 2001Date of Patent: September 10, 2002Assignee: Boehringer Ingelheim (Canada) Ltd.Inventors: Pierre Louis Beaulieu, Gulrez Fazal, James Gillard, George Kukolj, Volkhard Austel
-
Publication number: 20020123491Abstract: Compound represented by the structural formula 1Type: ApplicationFiled: December 14, 2000Publication date: September 5, 2002Inventors: Neng-Yang Shih, Ho-Jane Shue, Gregory A. Reichard, Sunil Paliwal, David J. Blythin, John J. Piwinski, Dong Xiao, Xiao Chen
-
Patent number: 6441005Abstract: Oxazolidinones and methods for their synthesis are provided. Further provided are methods of making biologically active oxazolidinones as well as pharmaceutically acceptable compositions comprising the oxazolidinones. Oxazolidinones as disclosed herein can be readily synthesized and used in a variety of applications including use as antimicrobial agents. In one embodiment, a variety of thioamidomethyloxazolidinones and methods for their synthesis and use are provided.Type: GrantFiled: July 26, 2000Date of Patent: August 27, 2002Assignee: Pharmacia & Upjohn CompanyInventors: Mikhail F. Gordeev, Gary W. Luehr, Dinesh V. Patel, Robert C. Gadwood
-
Patent number: 6426355Abstract: Compounds having the formula: wherein R1-R5, X and G are described herein and which are useful in the treatment of diseases associated with herpes viruses including human cytomegalovirus, herpes simplex viruses, Epstein-Barr virus, varicella-zoster virus, human herpesviruses-6 and -7, and Kaposi herpesvirus.Type: GrantFiled: September 27, 2000Date of Patent: July 30, 2002Assignee: American Home ProductsInventors: Jonathan Bloom, Kevin Curran, Martin DiGrandi, Russell Dushin, Thomas Jones, Stanley Lang, Adma Ross, Eugene A. Terefenko, Bryan O'Hara
-
Patent number: 6420400Abstract: Pharmaceutical compositions and compounds are provided. The compounds of the invention have anti-proliferative activity, and may promote apoptosis in cells lacking normal regulation of cell cycle and death. In one embodiment of the invention, formulations of the compounds in combination with a physiologically acceptable carrier are provided. The pharmaceutical formulations are useful in the treatment of hyperproliferative disorders, which disorders include tumor growth, lymphoproliferative diseases, angiogenesis.Type: GrantFiled: April 7, 2000Date of Patent: July 16, 2002Assignee: Kinetek Pharmaceuticals, Inc.Inventors: Zaihui Zhang, Jun Yan, Danny Leung, Shisen Wang, Penelope C. Costello, Jasbinder Sanghera
-
Publication number: 20020055523Abstract: The invention relates to substituted and unsubstituted 3H-benzo[1,2,3]oxathiazole 2,2-dioxides, 1,3-dihydrobenzo[1,2,5]thiadiazole 2,2-dioxides and 1,3-dihydro-benzo [c]isothiazole 2,2-dioxides, to their preparation and to their use in medicaments.Type: ApplicationFiled: August 9, 2001Publication date: May 9, 2002Inventors: Stefan Petry, Karl-Heinz Baringhaus, Swen Hoelder, Guenter Mueller
-
Publication number: 20020052510Abstract: This invention relates to novel N-linked sulfonamides of N-heterocyclic carboxylic acid and carboxylic acid isosteres, their preparation, and use for treating neurological disorders including physically damaged nerves and neurodegenerative diseases, and for treating alopecia and promoting hair growth.Type: ApplicationFiled: December 3, 1998Publication date: May 2, 2002Inventors: GREGORY S. HAMILTON, MARK H. NORMAN, YONG-QIAN WU
-
Publication number: 20020049238Abstract: Compounds with heterocyclic-hydroxyimino-fluorene nuclei that modulate and/or inhibit the activity of certain protein kinases are described. These compounds and pharmaceutical compositions containing them are capable of mediating tyrosine kinase signal transduction in order to modulate and/or inhibit unwanted cell proliferation. The invention is also directed to the therapeutic or prophylactic use of pharmaceutical compositions containing such compounds, and to methods of treating cancer as well as other disease states associated with unwanted angiogenesis and/or cellular proliferation, such as diabetic retinopathy, glaucoma, rheumatoid arthritis, and psoriasis, by administering effective amounts of such compounds.Type: ApplicationFiled: August 16, 2001Publication date: April 25, 2002Inventors: Wesley Kwon Mung Chong, Rohit Kumar Duvadie
-
Patent number: 6352985Abstract: A benzimidazole compound represented by the formula (I): wherein R3 is a carboxyl group, a esterified carboxyl group, an amidated carboxyl group, an amino group, an amido group, or a sulfonyl group, or their pharmaceutically acceptable salts. Because of their blood sugar-depressing effect or PDE5 inhibitory effect, these compounds or salts thereof are useful as medicines for treating impaired glucose tolerance, diabetes, diabetic complications, syndrome of insulin resistance, hyperlipidemia, atherosclerosis, cardiovascular disorders, hyperglycemia, or hypertension; or stenocardia, hypertension, pulmonary hypertension, congestive heart failure, glomerulopathy, tubulointerstitial disorders, renal failure, atherosclerosis, angiostenosis, distal angiopathy, cerebral apoplexy, chronic reversible obstructions, allergic rhinitis, urticaria, glaucoma, diseases characterized by enteromotility disorders, impotence, diabetic complications, nephritis, cancerous cachexia, or restenosis after PTCA.Type: GrantFiled: January 28, 2000Date of Patent: March 5, 2002Assignee: Fujisawa Pharmaceutical Co., Ltd.Inventors: Noritsugu Yamasaki, Takafumi Imoto, Yoshiyuki Murai, Takahiro Hiramura, Teruo Oku, Kouzou Sawada
-
Patent number: 6348480Abstract: The present invention is directed to drugs, in particular, pyrazole derivatives represented by the following general formula (I) which have a calcium release-activated calcium channel inhibitory effect and medicinal compositions, in particular, calcium release-activated calcium channel inhibitors containing the above compounds as the active ingredient, wherein each substituent is defined in the specification. The present invention also relates to a pharmaceutical composition containiing an effective amount of the compound of formula (I) and a pharmaceutically effective carrier. The present invention further relates to methods of treatment of diseases associated with calcium release-activated calcium channels, diseases associated with IL-2 production, and methods of treatment of allergic, inflammatory or auto-immune diseases.Type: GrantFiled: April 7, 2000Date of Patent: February 19, 2002Assignee: Yamanouchi Pharmaceutical Co., Ltd.Inventors: Hirokazu Kubota, Yasuhiro Yonetoku, Keizou Sugasawa, Masashi Funatsu, Souichirou Kawazoe, Akira Toyoshima, Yoshinori Okamoto, Jun Ishikawa, Makoto Takeuchi
-
Patent number: 6342245Abstract: The present invention is concerned with novel pharmaceutical compositions of lipid lowering agents which can be administered to a mammal suffering from hyperlipidemia, obesitas or atherosclerosis, whereby a single such dosage form can be administered once daily, and in addition at any time of the day independently of the food taken in by said mammal. These novel compositions comprise particles obtainable by melt-extruding a mixture comprising a lipid lowering agent and an appropriate water-soluble polymer and subsequently milling said melt-extruded mixture.Type: GrantFiled: April 24, 2000Date of Patent: January 29, 2002Assignee: Janssen Pharmaceutica N.V.Inventors: Lieven Baert, Geert Verreck
-
Patent number: 6340697Abstract: Various oxime derivatives are provided, which do not cause any chemical damage to plants and which exhibit sufficient effectiveness against various plant diseases. The oxime derivatives are expressed by two general chemical formulas (1) and (2), as follows. Agricultural chemicals and plant disease control chemicals are also provided which contain the above mentioned oxime derivatives as active ingredients. Test results of these agricultural chemicals and the plant disease control chemicals are proved to be very effective for downey mildews and late blights or Phytophthora rot etc.Type: GrantFiled: June 12, 2000Date of Patent: January 22, 2002Assignee: Dainippon Ink and Chemicals, Inc.Inventors: Takeo Kobori, Tomoko Goto, Hitoshi Kondo, Hiroyuki Tsuboi, Mika Iiyama, Toru Asada, Takashi Goto
-
Patent number: 6337341Abstract: A 1,2,3-thiadiazole derivative represented by general formula (I) or a salt thereof: wherein R1 is H, (halo) C1-C4 alkyl, 5- or 6-membered heterocycle containing 1 to 3 same or different O, N or S or the like, A is a group of the following formulas: wherein R2 and R3 are H, halogen, cyano, formyl, alkylthio, alkoxycarbonyl, substituted or unsubstituted phenyl, or the like, or R2 and R3, taken conjointly, may form a 3- to 7-membered ring including a C2-C6 alkylene group which may be intercepted by —O—, —S(O)n— (n is 0-2), —CO— or —NR8— (R8 is H, halogen or the like), B is cyano or an unsubstituted or substituted 5- or 6-membered heterocycle containing 1-3 hetero atoms selected from O, N and S, and m is 0-4; salts thereof; an agrohorticultural disease controller containing said derivative or salt; and method for using said disease controller.Type: GrantFiled: September 19, 2000Date of Patent: January 8, 2002Assignee: Nihon Nohyaku Co., Ltd.Inventors: Kenji Tsubata, Takashi Shimaoka, Osamu Sampei, Yoshitaka Taniyama, Kazuhiro Takagi, Tsutomu Nishiguchi, Sohkichi Tajima
-
Patent number: 6331537Abstract: This invention relates to novel N-heteorocyclic carboxylic acids and carboxylic acid isosteres, their preparation and use for treating neurological disorders including physically damaged nerves and neurodengenerative diseases, for treating alopecia and promoting hair growth, for treating vision disorders and/or improving vision, and for treating memory impairment and/or enhancing memory performance by administering such compounds.Type: GrantFiled: December 2, 1999Date of Patent: December 18, 2001Assignee: GPI Nil Holdings, Inc.Inventors: Gregory S. Hamilton, Mark H. Norman, Yong-Qian Wu
-
Patent number: 6331640Abstract: A compound of formula 1a which is useful for treating reperfusion injury, and salts, prodrugs, and related compounds.Type: GrantFiled: September 29, 1999Date of Patent: December 18, 2001Assignee: Hoffmann-La Roche Inc.Inventors: Nader Fotouhi, Paul Gillespie, Robert William Guthrie, Sherrie Lynn Pietranico-Cole, Weiya Yun
-
Patent number: 6329373Abstract: A compound of formula (I) wherein X is a —CONHOH group and the R groups are defined in the claims. The compounds are inhibitors of matrix metalloproteinases involved in tissue degradation and inhibitors of the release of tumour necrosis factor from cells.Type: GrantFiled: January 7, 2000Date of Patent: December 11, 2001Assignee: British Biotech Pharmaceuticals, Ltd.Inventors: Fionna Mitchell Martin, Christopher Norman Lewis, Mark Whittaker
-
Patent number: 6329421Abstract: The invention encompasses the novel compound of Formula I as well as a method of treating cyclooxygenase-2 mediated diseases comprising administration to a patient in need of such treatment of a non-toxic therapeutically effective amount of a compound of Formula I. The invention also encompasses certain pharmaceutical compositions for treatment of cyclooxygenase-2 mediated diseases comprising compounds of Formula I.Type: GrantFiled: February 25, 1997Date of Patent: December 11, 2001Assignee: Merck Frosst Canada & Co.Inventors: Petpiboon Prasit, Daniel Guay, Zhaoyin Wang, Serge Leger, Michel Therien
-
Patent number: 6320050Abstract: 2,3-Di-substituted N-heteroaromatic propionamides with said substitution at the 2-position being a substituted phenyl group and at the 3-position being a cycloalkyl ring, said propionamides being glucokinase activators which increase insulin secretion in the treatment of type II diabetes.Type: GrantFiled: March 15, 2000Date of Patent: November 20, 2001Assignee: Hoffmann-La Roche Inc.Inventors: Fred Thomas Bizzarro, Wendy Lea Corbett, Joseph Francis Grippo, Nancy-Ellen Haynes, George William Holland, Robert Francis Kester, Ramakanth Sarabu
-
Patent number: 6319933Abstract: The present invention is directed to new 1-(1H-1,2,4-triazol-1-yl)butan-2-ol derivatives of the formula (I), and pharmaceutically acceptable salts thereof wherein Q, R, X, Y and Z are the same as defined in the claims and the description. 1-(1H-1,2,4-triazol-1-yl)butan-2-ol derivatives of the present invention have antifungal activity and are useful for the treatment of fungal diseases.Type: GrantFiled: March 22, 2001Date of Patent: November 20, 2001Assignee: Basilea Pharmaceutica AGInventors: Susumu Komiyama, Nobuo Shimma, Takuo Tsukuda
-
Patent number: 6319944Abstract: Compounds represented by formula I: or a pharmaceutically acceptable salt or hydrate thereof, are disclosed. Pharmaceutical compositions and methods of treatment are also included.Type: GrantFiled: May 4, 2000Date of Patent: November 20, 2001Assignee: Merck & Co., Inc.Inventors: Christopher F. Claiborne, Nigel J. Liverton, Brian Libby, Neil R. Curtis, Janusz Kulagowski
-
Publication number: 20010041726Abstract: The present invention describes novel nitrosated and/or nitrosylated cyclooxygenase 2 (COX-2) inhibitors and novel compositions comprising at least one nitrosated and/or nitrosylated cyclooxygenase 2 (COX-2) inhibitor, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or optionally, at least one therapeutic agent, such as, steroids, nonsteroidal antiinflammatory compounds (NSAID), 5-lipoxygenase (5-LO) inhibitors, leukotriene B4 (LTB4) receptor antagonists, leukotriene A4 (LTA4) hydrolase inhibitors, 5-HT agonists, 3-hydroxy-3-methylglutaryl coenzyme A (HMGCoA) inhibitors, H antagonists, antineoplastic agents, antiplatelet agents, decongestants, diuretics, sedating or non-sedating anti-histamines, inducible nitric oxide synthase inhibitors, opioids, analgesics, Helicobacter pylori inhibitors, proton pump inhibType: ApplicationFiled: December 22, 2000Publication date: November 15, 2001Inventors: Ramani R. Bandarage, Upul K. Bandarage, Xinqin Fang, David S. Garvey, L. Gordon Letts, Joseph D. Schroeder, Sang William Tam
-
Patent number: 6313154Abstract: A bis-thiadiazole derivative represented by general formula (I): wherein R1 and R2 represent H, C1-C8 alkyl, halo C1-C4 alkyl, unsubstituted or substituted phenyl, 5- or 6-membered heterocycle containing 1 to 3 hetero atoms selected from O, S and N, or the like; X1 and X2 represent O or S; Y1 and Y2 represent O, S or —N(R3)—; R represents C0-C30 alkylene. —(C)a(R3)(R4)— (R3 and R4 represent H, halogen, OH, C1-C4 alkyl, halo C1-C4 alkyl or the like) or the like; and a is 0 to 30; or a salt thereof, and an agrohorticultural disease controller containing said derivative or salt as an active ingredient.Type: GrantFiled: March 26, 1999Date of Patent: November 6, 2001Assignee: Nihon Nohyaku Co., Ltd.Inventors: Kenji Tsubata, Takashi Shimaoka, Kazuhiro Takagi, Koji Baba, Sohkichi Tajima
-
Patent number: 6303620Abstract: Disclosed are 4,4-disubstituted and 3,3-disubstituted piperidine compounds of formula I wherein D, E, G, J, R1, a, b, c, and d are defined in the specification, compositions containing them, and their use for treating medical disorders resulting from a deficiency in growth hormone.Type: GrantFiled: May 6, 1999Date of Patent: October 16, 2001Assignee: Novo Nordisk A/SInventors: Thomas Kruse Hansen, Michael Ankersen
-
Patent number: 6300325Abstract: This invention relates to novel benzo-2-triazole substituted compounds, pharmaceutical compositions, processes for their preparation, and use thereof in treating IL-8, GRO&agr;, GRO&bgr;, GRO&ggr; and NAP-2 mediated diseases.Type: GrantFiled: July 9, 1999Date of Patent: October 9, 2001Assignee: SmithKline Beecham CorporationInventors: Katherine L. Widdowson, Melvin C. Rutledge
-
Patent number: 6297196Abstract: Benzoyl derivatives of the formula (I), process for their preparation and their use as herbicides and plant growth regulators are described. In this formula (I), R1, R2, R3, R4 and R5 are various organic radicals, Q is isothiazole, isoxazole, cyclohexanedione or a &bgr;-ketonitrile radical and A, B, E and X are divalent units containing one or more atoms.Type: GrantFiled: September 2, 1999Date of Patent: October 2, 2001Assignee: Hoechst Schering AgrEvo GmbHInventors: Andreas Van Almsick, Lothar Willms, Thomas Auler, Hermann Bieringer, Christopher Rosinger
-
Patent number: 6281238Abstract: This invention provides compounds of Formula I having the structure wherein B and D are each, independently, hydrogen, halogen, —CN, alkyl of 1-6 carbon atoms, aryl, or aralkyl of 6-12 carbon atoms; R1 is hydrogen, alkyl of 1-6 carbon atoms, —CH(R2)W, —C(CH3)2CO2R3, 5-thiazolidine-2,4-dione, —CH(R4)CH2CO2R3, —COR3, or —PO3(R3)2; R2 is hydrogen, alkyl of 1-6 carbon atoms, aralkyl of 6-12 carbon atoms, aryl, —CH2(1H-imidazol-4-yl), —CH2(3-1H-indolyl), —CH2CH2(1,3-dioxo-1,3-dihydro-isoindol-2-yl), —CH2CH2(1-oxo-1,3-dihydro-isoindol-2-yl), or —CH2(3-pyridyl); W is —CO2R3, —CONH2, —CONHOH, —CN, CONH(CH2)2CN, 5-tetrazole, or —PO3(R3)2; R3 is hydrogen, alkyl of 1-6 carbon atoms, or aryl; R4 is hydrogen or alkyl of 1-6 carbon atoms; or a pharmaceutically acceptable salt thereof, which are useful in treating metabolic disorders related to insulin resistance or hyperglycemia.Type: GrantFiled: March 16, 2000Date of Patent: August 28, 2001Assignee: American Home Products CorporationInventors: Jay E. Wrobel, Zenan Li
-
Patent number: 6265583Abstract: The present invention relates to cyclic sulfone moiety-containing hydroxyethylamine protease inhibitor compounds and pharmaceutical or method of use therefor, particularly as an inhibitor of HIV protease.Type: GrantFiled: October 22, 1998Date of Patent: July 24, 2001Assignees: G. D. Searle & Co., Monsanto CompanyInventors: Deborah E. Bertenshaw, Daniel Getman, Robert M. Heintz, John J. Talley, Kathryn L. Reed, Robert Alan Chrusciel, Michael Clare
-
Patent number: 6262089Abstract: New compounds have the formula: wherein R, R1, X and Y have the meanings described herein. Methods are set forth for synthesizing these compounds and using these compounds to treat diseases associated with amyloidosis, such as Alzheimer's disease, maturity onset diabetes mellitus, familial amyloid polyneuropathy, scrapie, and Kreuzfeld-Jacob disease.Type: GrantFiled: February 16, 2000Date of Patent: July 17, 2001Assignee: Hoffman-La Roche Inc.Inventors: Cornelia Hertel, Torsten Hoffmann, Roland Jakob-Roetne, Roger David Norcross
-
Patent number: 6252084Abstract: A class of novel 1H-indole-3-acetamides is disclosed together with the use of such indole compounds for inhibiting sPLA2 mediated release of fatty acids for treatment of conditions such as septic shock.Type: GrantFiled: October 31, 1997Date of Patent: June 26, 2001Assignee: Eli Lilly and CompanyInventors: Nicholas J. Bach, Robert D. Dillard, Susan E. Draheim, Robert B. Hermann, Richard W. Schevitz
-
Patent number: 6225329Abstract: The present invention provides novel compounds of Formula 1, compositions containing these compounds, methods of their use, and methods of their manufacture, where such compounds are pharmacologically useful inhibitors of Protein Tyrosine Phosphatases (PTPase's) such as PTP1B, CD45, SHP-1, SHP-2, PTP&agr;, LAR and HePTP or the like, wherein A, R1, R2, R3, R4, R16 and R17 are as defined in the specification.Type: GrantFiled: March 9, 1999Date of Patent: May 1, 2001Assignee: Novo Nordisk A/SInventors: Lutz Stefan Richter, Henrik Sune Andersen, Josef Vagner, Claus Bekker Jeppesen, Niels Peter Hundahl Møller, Sven Branner, Jing Su, Farid Bakir, Luke Milburn Judge
-
Patent number: 6211210Abstract: The invention encompasses compounds of Formula I as well as a method of treating COX-2 mediated diseases comprising administration to a patient in need of such treatment of a non-toxic therapeutically effective amount of a compound of Formula I. The invention also encompasses certain pharmaceutical compositions for treatment of COX-2 mediated diseases comprising compounds of Formula I.Type: GrantFiled: April 28, 2000Date of Patent: April 3, 2001Assignee: Merck Frosst Canada & Co.Inventors: Cheuk Kun Lau, Chun-Sing Li, Cameron Black, Michel Therien, Jacques Yves Gauthier